Hol dir die App Get the App
⭐️⭐️⭐️⭐️⭐️
44 Bewertungen
Zur App
DAX 26.458,50 0,19% Dow Jones 53.715,50 -0,27% MDAX 32.496,90 0,40% Nikkei 225 68.623,30 -0,68% S&P 500 7.782,88 -0,23% STOXX Europe 50 6.545,00 -0,27% Nasdaq 100 30.026,10 -0,20% Bitcoin 63.010,99 USD 0,28% Gold 140,71 USD 0,02% EUR/USD 1,16 USD 0,33%
DAX 26.458,50 0,19% Dow Jones 53.715,50 -0,27% MDAX 32.496,90 0,40% Nikkei 225 68.623,30 -0,68% S&P 500 7.782,88 -0,23% STOXX Europe 50 6.545,00 -0,27% Nasdaq 100 30.026,10 -0,20% Bitcoin 63.010,99 USD 0,28% Gold 140,71 USD 0,02% EUR/USD 1,16 USD 0,33%
+49 (0) 172 414 333 6
Wertpapiere

Aktie US88025U1097

10x Genomics, Inc.

48,41 €

  • 0,00 €
  • |
  • 0,00 %

Your browser does not support the canvas element.

  • Aug.
  • Okt.
  • Nov.
  • Jan.
  • März
  • Mai
  • Juni
  • Aug.
  • 5
  • 20
  • 30
  • 45
  • 55

ERTRÄGE

Dieses Unternehmen zahlt derzeit keine Dividende. Mit einem Nettogewinn von -76 Mio. € und einem operativen Cashflow von 89 Mio. € hätte das Unternehmen die Kapazität für Ausschüttungen, verzichtet aber bewusst. Dies deutet auf strategische Reinvestitionen oder eine Phase intensiver Expansion hin.

0,00 €

Jährliche Dividende

0,00 %

Rendite

0,00 %

Dividenden-Wachstum

0,00 %

Ausschüttungsquote

  • 100 %

    G

  • 100 %

    OCF

UNTERNEHMEN

641,8 Mio. $

Umsatz

  • -76,3 Mio.

    NG

  • 249,6 Mio.

    F&E

  • 441,8 Mio.

    BG

  • 641,8 Mio.

    U

5,08 %

Umsatz-Wachstum

  • 22

  • 23

  • 24

  • 25

  • 26

-76,3 Mio. $

Nettogewinn

  • -13,5 %

    ROE
  • -11,9 %

    ROS
  • -8,0 %

    ROA
  • -7,2 %

    GPM

88,5 Mio. $

Operativer Cashflow

  • FCF

    92 %
  • 8 %

    CapEx

567,1 Mio. $

Eigenkapital

  • EK 73 %
  • 27 % FK

1.306

Mitarbeiter

  • 491.434,9 $

    Umsatz / MA
  • -58.438,0 $

    Gewinn / MA

KGV

-18,62 $

KBV

1,91 $

KCV

17,43 $

KUV

2,22 $

EV/EBITDA

-26,88 $

EV/EBIT

-13,68 $

EV/FCF

15,29 $

EV/Umsatz

1,95 $

EnterpriseValue

1,2 Mrd. $

Eigenkapitalrendite

-13,46 %

Umsatzrendite

-11,89 %

EBIT-Marge

-14,22 %

EBITDA-Marge

-7,24 %

Kapitalumschlag

0,82 $

Gesamtkapitalrendite

-7,97 %

Eigenkapitalquote

0,59 $

Fremdkapitalquote

0,22 $

Verschuldungsgrad

0,38 $

Dyn. Verschuldungsgrad

2,41 $

Sachinvestitionsquote

-0,078 $

Anlagendeckungsgrad 1

0,59 $

Anlagendeckungsgrad 2

0,51 $

Liquidität 1. Grades

3,20 $

Liquidität 2. Grades

3,93 $

Liquidität 3. Grades

5,11 $

Dividende pro Aktie

0,00 $

Dividendenrendite

0,00 %

Ausschüttungsquote

0,00 %

Buchwert pro Aktie

6,02 $

Cashflow pro Aktie

0,72 $
Stand: 30.09.2025 TTM

Fakten

  • Sitz

    USA

  • Hauptsitz

    Pleasanton

  • Börsengang

    12.09.2019

  • Ausstehende Aktien

    123,55 Mio.

  • Mitarbeiter

    1,31 Tsd.

  • Währung

    USD

  • Sektor

    Gesundheitswesen

  • Industrie

    Medical - Healthcare Information Services

  • Börse

    NASDAQ

  • Ticker

    TXG

  • Webseite

    10xgenomics.com

Aktie

Unternehmensinfos

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmac...
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.